Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer

Molecular Therapy

Volumn 25, Issue 1, 2017, Pages 249-258

  Mohammed, Somala ^a,b   Sukumaran, Sujita ^a,b   Bajgain, Pradip ^a,b   Watanabe, Norihiro ^a   Heslop, Helen E ^a   Rooney, Cliona M ^a   Brenner, Malcolm K ^a   Fisher, William E ^b   Leen, Ann M ^a   Vera, Juan F ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CAR; chimeric antigen receptor; ICR; IL 4; IL 4R; IL 7R; inhibitory cytokines; inverted cytokine receptor; pancreatic cancer; PSCA; T cell therapy; tumor microenvironment

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 7 RECEPTOR; PROSTATE STEM CELL ANTIGEN; CYTOKINE; HYBRID PROTEIN; INTERLEUKIN 4; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SELECTION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; SAFETY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL PROLIFERATION; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MICE; PANCREATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; TUMOR MICROENVIRONMENT;

EID: 85016297609     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2016.10.016     Document Type: Article

References (55)

1. 1 Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., June, C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365 (2011), 725–733.
2. 2 Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
3. 3 Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 2014, 224ra25.
4. 4 Savoldo, B., Ramos, C.A., Liu, E., Mims, M.P., Keating, M.J., Carrum, G., Kamble, R.T., Bollard, C.M., Gee, A.P., Mei, Z., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121 (2011), 1822–1826.
5. 5 Chia, W.K., Teo, M., Wang, W.W., Lee, B., Ang, S.F., Tai, W.M., Chee, C.L., Ng, J., Kan, R., Lim, W.T., et al. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Mol. Ther. 22 (2014), 132–139.
6. 6 Straathof, K.C., Bollard, C.M., Popat, U., Huls, M.H., Lopez, T., Morriss, M.C., Gresik, M.V., Gee, A.P., Russell, H.V., Brenner, M.K., et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes. Blood 105 (2005), 1898–1904.
7. 7 Wente, M.N., Jain, A., Kono, E., Berberat, P.O., Giese, T., Reber, H.A., Friess, H., Büchler, M.W., Reiter, R.E., Hines, O.J., Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 31 (2005), 119–125.
8. 8 Katari, U.L., Keirnan, J.M., Worth, A.C., Hodges, S.E., Leen, A.M., Fisher, W.E., Vera, J.F., Engineered T cells for pancreatic cancer treatment. HPB (Oxford) 13 (2011), 643–650.
9. 9 Abate-Daga, D., Lagisetty, K.H., Tran, E., Zheng, Z., Gattinoni, L., Yu, Z., Burns, W.R., Miermont, A.M., Teper, Y., Rudloff, U., et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum. Gene Ther. 25 (2014), 1003–1012.
10. 10 Saeki, N., Gu, J., Yoshida, T., Wu, X., Prostate stem cell antigen: A Jekyll and Hyde molecule?. Clin. Cancer Res. 16 (2010), 3533–3538.
11. 11 Wolpin, B.M., O'Reilly, E.M., Ko, Y.J., Blaszkowsky, L.S., Rarick, M., Rocha-Lima, C.M., Ritch, P., Chan, E., Spratlin, J., Macarulla, T., et al. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann. Oncol. 24 (2013), 1792–1801.
12. 12 Anurathapan, U., Chan, R.C., Hindi, H.F., Mucharla, R., Bajgain, P., Hayes, B.C., Fisher, W.E., Heslop, H.E., Rooney, C.M., Brenner, M.K., et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol. Ther. 22 (2014), 623–633.
13. 13 Rucki, A.A., Zheng, L., Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies. World J. Gastroenterol. 20 (2014), 2237–2246.
14. 14 Erkan, M., Michalski, C.W., Rieder, S., Reiser-Erkan, C., Abiatari, I., Kolb, A., Giese, N.A., Esposito, I., Friess, H., Kleeff, J., The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 6 (2008), 1155–1161.
15. 15 Ochi, A., Nguyen, A.H., Bedrosian, A.S., Mushlin, H.M., Zarbakhsh, S., Barilla, R., Zambirinis, C.P., Fallon, N.C., Rehman, A., Pylayeva-Gupta, Y., et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J. Exp. Med. 209 (2012), 1671–1687.
16. 16 Gocheva, V., Wang, H.W., Gadea, B.B., Shree, T., Hunter, K.E., Garfall, A.L., Berman, T., Joyce, J.A., IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 24 (2010), 241–255.
17. 17 von Bernstorff, W., Voss, M., Freichel, S., Schmid, A., Vogel, I., Johnk, C., Henne-Bruns, D., Kremer, B., Kalthoff, H., Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res. 7 (2001), 925s–932s.
18. 18 Prokopchuk, O., Liu, Y., Henne-Bruns, D., Kornmann, M., Interleukin-4 enhances proliferation of human pancreatic cancer cells: Evidence for autocrine and paracrine actions. Br. J. Cancer 92 (2005), 921–928.
19. 19 Rabinovich, G.A., Gabrilovich, D., Sotomayor, E.M., Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25 (2007), 267–296.
20. 20 Feurino, L.W., Fisher, W.E., Bharadwaj, U., Yao, Q., Chen, C., Li, M., Current update of cytokines in pancreatic cancer: Pathogenic mechanisms, clinical indication, and therapeutic values. Cancer Invest. 24 (2006), 696–703.
21. 21 Leen, A.M., Rooney, C.M., Foster, A.E., Improving T cell therapy for cancer. Annu. Rev. Immunol. 25 (2007), 243–265.
22. 22 Peggs, K.S., Quezada, S.A., Allison, J.P., Cancer immunotherapy: Co-stimulatory agonists and co-inhibitory antagonists. Clin. Exp. Immunol. 157 (2009), 9–19.
23. 23 Antonarakis, E.S., Carducci, M.A., Eisenberger, M.A., Denmeade, S.R., Slovin, S.F., Jelaca-Maxwell, K., Vincent, M.E., Scher, H.I., Morris, M.J., Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: A PCCTC trial. Cancer Chemother. Pharmacol. 69 (2012), 763–771.
24. 24 Yang, W.B., Cai, F., Cheng, C.T., Cao, G., Qing, Z.Y., [Role of prostate stem cell antigen in human pancreatic carcinoma: A tissue microarray-based study]. Nan Fang Yi Ke Da Xue Xue Bao 29 (2009), 2135–2137.
25. 25 Gu, Z., Thomas, G., Yamashiro, J., Shintaku, I.P., Dorey, F., Raitano, A., Witte, O.N., Said, J.W., Loda, M., Reiter, R.E., Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19 (2000), 1288–1296.
26. 26 Ansari, D., Gustafsson, A., Andersson, R., Update on the management of pancreatic cancer: Surgery is not enough. World J. Gastroenterol. 21 (2015), 3157–3165.
27. 27 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30.
28. 28 Dotti, G., Gottschalk, S., Savoldo, B., Brenner, M.K., Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 257 (2014), 107–126.
29. 29 Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med., 5, 2013, 177ra38.
30. 30 Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 (2013), 1509–1518.
31. 31 Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., June, C.H., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3, 2011, 95ra73.
32. 32 Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., Stetler-Stevenson, M., Phan, G.Q., Hughes, M.S., Sherry, R.M., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119 (2012), 2709–2720.
33. 33 Chmielewski, M., Hahn, O., Rappl, G., Nowak, M., Schmidt-Wolf, I.H., Hombach, A., Abken, H., T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 143 (2012), 1095–1107.
34. 34 Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G., Chew, A., Zhao, Y., Levine, B.L., Albelda, S.M., et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2 (2014), 112–120.
35. 35 Maliar, A., Servais, C., Waks, T., Chmielewski, M., Lavy, R., Altevogt, P., Abken, H., Eshhar, Z., Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 143 (2012), 1375–1384.
36. 36 Nishio, N., Diaconu, I., Liu, H., Cerullo, V., Caruana, I., Hoyos, V., Bouchier-Hayes, L., Savoldo, B., Dotti, G., Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 74 (2014), 5195–5205.
37. 37 Song, D.G., Ye, Q., Carpenito, C., Poussin, M., Wang, L.P., Ji, C., Figini, M., June, C.H., Coukos, G., Powell, D.J. Jr., In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71 (2011), 4617–4627.
38. 38 Zhao, Y., Wang, Q.J., Yang, S., Kochenderfer, J.N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S.A., Morgan, R.A., A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183 (2009), 5563–5574.
39. 39 Pegram, H.J., Lee, J.C., Hayman, E.G., Imperato, G.H., Tedder, T.F., Sadelain, M., Brentjens, R.J., Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119 (2012), 4133–4141.
40. 40 Vera, J.F., Hoyos, V., Savoldo, B., Quintarelli, C., Giordano Attianese, G.M., Leen, A.M., Liu, H., Foster, A.E., Heslop, H.E., Rooney, C.M., et al. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol. Ther. 17 (2009), 880–888.
41. 41 Hoyos, V., Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H.E., Rooney, C.M., Brenner, M.K., Dotti, G., Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24 (2010), 1160–1170.
42. 42 Bollard, C.M., Rössig, C., Calonge, M.J., Huls, M.H., Wagner, H.J., Massague, J., Brenner, M.K., Heslop, H.E., Rooney, C.M., Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99 (2002), 3179–3187.
43. 43 Lacuesta, K., Buza, E., Hauser, H., Granville, L., Pule, M., Corboy, G., Finegold, M., Weiss, H., Chen, S.Y., Brenner, M.K., et al. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J. Immunother. 29 (2006), 250–260.
44. 44 Leen, A.M., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J., Yanagisawa, R., Anurathapan, U., Rendon, D., Heslop, H.E., Rooney, C.M., et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol. Ther. 22 (2014), 1211–1220.
45. 45 Prosser, M.E., Brown, C.E., Shami, A.F., Forman, S.J., Jensen, M.C., Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol. Immunol. 51 (2012), 263–272.
46. 46 Minagawa, K., Zhou, X., Mineishi, S., Di Stasi, A., Seatbelts in CAR therapy: How safe are cars?. Pharmaceuticals (Basel) 8 (2015), 230–249.
47. 47 Logsdon, C.D., Simeone, D.M., Binkley, C., Arumugam, T., Greenson, J.K., Giordano, T.J., Misek, D.E., Kuick, R., Hanash, S., Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 63 (2003), 2649–2657.
48. 48 van Roon, J.A., Glaudemans, K.A., Bijlsma, J.W., Lafeber, F.P., Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann. Rheum. Dis. 62 (2003), 113–119.
49. 49 Lee, L.F., Axtell, R., Tu, G.H., Logronio, K., Dilley, J., Yu, J., Rickert, M., Han, B., Evering, W., Walker, M.G., et al. IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis. Sci. Transl. Med., 3, 2011, 93ra68.
50. 50 Lin, J.X., Migone, T.S., Tsang, M., Friedmann, M., Weatherbee, J.A., Zhou, L., Yamauchi, A., Bloom, E.T., Mietz, J., John, S., et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2 (1995), 331–339.
51. 51 Barata, J.T., Cardoso, A.A., Nadler, L.M., Boussiotis, V.A., Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 98 (2001), 1524–1531.
52. 52 Jiang, Q., Li, W.Q., Hofmeister, R.R., Young, H.A., Hodge, D.R., Keller, J.R., Khaled, A.R., Durum, S.K., Distinct regions of the interleukin-7 receptor regulate different Bcl2 family members. Mol. Cell. Biol. 24 (2004), 6501–6513.
53. 53 Wurster, A.L., Tanaka, T., Grusby, M.J., The biology of Stat4 and Stat6. Oncogene 19 (2000), 2577–2584.
54. 54 Leyton, J.V., Olafsen, T., Lepin, E.J., Hahm, S., Bauer, K.B., Reiter, R.E., Wu, A.M., Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin. Cancer Res. 14 (2008), 7488–7496.
55. 55 Leyton, J.V., Olafsen, T., Sherman, M.A., Bauer, K.B., Aghajanian, P., Reiter, R.E., Wu, A.M., Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng. Des. Sel. 22 (2009), 209–216.